Skip to NavigationSkip to content


Kings College London launches trial investigating the effectiveness of ibuprofen in COVID-19 patients

Photo Sarah-Rose/

Kings College London has launched a clinical trial to investigate how effective a formulation of ibuoprofen is in reducing respiratory failure in coronavirus patients.

The LIBERATE trial will be a collaboration between the College, London’s Guy’s & St Thomas’s NHS Foundation Trust and the SEEK group.

GSK wins case against Reckitt Benckiser over misleading ad campaign

GlaxoSmithKline is celebrating as it emerges that the UK pharma giant triumphed in its legal battle against Reckitt Benckiser after accusing the rival firm of misleading consumers by directly comparing its product Nurofen to paracetamol in its advertising campaign, when GSK manufactures the branded version, Panadol.

Ibuprofen linked to 31% increase in risk of cardiac arrest

A study emerging from Denmark has found that the use of over-the-counter pain killer, Ibuprofen, is associated with an increased risk of cardiac arrest. In particular, the research warned against the view of nonsteroidal anti-inflammatory drugs (NSAID) as without risk and advised against people using the pain killers who had pre-existing cardiovascular problems.

Pfizer’s Celebrex found to be safe on hearts after 10-year clinical study

Pfizer’s drug, Celebrex, has been vindicated as of equivalent safety, or better, than ibuprofen and naproxen, after a 10-year study. Celebrex (celecoxib) is used as a type of painkiller for those suffering from arthritis.

Celebrex belongs to a class of drugs called Cox-2 inhibitors. Doubts have been held about the safety of the drug after MSD’s Vioxx, also a Cox-2 inhibitor, was withdrawn from the market in 2004, after it was linked to an increase in the risk of heart attacks.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches